argenx NV ADR (ARGX)vsHalozyme Therapeutics Inc (HALO)
ARGX
argenx NV ADR
$697.05
+2.89%
HEALTHCARE · Cap: $42.05B
HALO
Halozyme Therapeutics Inc
$63.24
+1.93%
HEALTHCARE · Cap: $7.32B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 203% more annual revenue ($4.24B vs $1.40B). ARGX leads profitability with a 30.5% profit margin vs 22.7%. HALO trades at a lower P/E of 24.2x. HALO earns a higher WallStSmart Score of 70/100 (B).
ARGX
Buy63
out of 100
Grade: C+
HALO
Strong Buy70
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-526.8%
Fair Value
$133.14
Current Price
$697.05
$563.91 premium
Margin of Safety
+33.6%
Fair Value
$119.81
Current Price
$63.24
$56.57 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Revenue surging 73.0% year-over-year
Every $100 of equity generates 20 in profit
Growing faster than its price suggests
Strong operational efficiency at 27.4%
Strong operational efficiency at 56.3%
Revenue surging 51.6% year-over-year
Keeps 23 of every $100 in revenue as profit
Earnings expanding 36.2% YoY
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 31.9%
ROE of 1.5% — below average capital efficiency
Trading at 154.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Revenue Growth, Return on Equity. Profitability is solid with margins at 30.5% and operating margin at 27.4%. Revenue growth of 73.0% demonstrates continued momentum.
Bull Case : HALO
The strongest argument for HALO centers on Operating Margin, Revenue Growth, Profit Margin. Profitability is solid with margins at 22.7% and operating margin at 56.3%. Revenue growth of 51.6% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : HALO
The primary concerns for HALO are Return on Equity, Price/Book.
Key Dynamics to Monitor
HALO carries more volatility with a beta of 1.02 — expect wider price swings.
ARGX is growing revenue faster at 73.0% — sustainability is the question.
ARGX generates stronger free cash flow (407M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
HALO scores higher overall (70/100 vs 63/100), backed by strong 22.7% margins and 51.6% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Halozyme Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?